RANKL/RANK/OPG: key therapeutic target in bone oncology.

Cancer is one of the major leading causes of death all over the world. Primary and secondary bone tumors can significantly deteriorate the quality of life (QOL) and the activity of daily living (ADL) of the patients. These unwelcome diseases become a social and economic burden seriously. Thus, more effective therapies for both primary and secondary bone tumors are actually required. Bone homeostasis depends on the strictly balanced activities between bone formation by osteoblasts and bone resorption by osteoclasts. Imbalance of bone formation and resorption results in various bone diseases. Both primary and secondary bone tumors develop in the unique environment bone, it is therefore necessary to understand bone cell biology in tumoral bone environment. Recent findings strongly revealed the significant involvement of the receptor activator of nuclear factor kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) triad, the key regulators of bone remodeling in bone oncology. Indeed, RANKL/RANK blocking successfully prevented the development of bone metastases. Furthermore, some cancer cells express RANK which is involved in tumor cell migration. Thus, the regulation of this triad will be a rational, encouraged therapeutic hot spot in bone oncology. In this review, we summarize the accumulating knowledge of the RANKL/RANK/OPG triad and discuss about its therapeutic capability in primary and secondary bone tumors.

[1]  D. Heymann,et al.  Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. , 2007, Oncology reports.

[2]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[3]  B. Oyajobi.  Multiple myeloma/hypercalcemia , 2007, Arthritis research & therapy.

[4]  D. Heymann,et al.  RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases , 2007, Cellular and Molecular Life Sciences.

[5]  L. Hofbauer,et al.  Osteoprotegerin expression in dendritic cells increases with maturation and is NF‐κB‐dependent , 2007, Journal of cellular biochemistry.

[6]  B. Le Goff,et al.  Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.

[7]  B. Le Goff,et al.  DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. , 2007, Bone.

[8]  M. Dimopoulos,et al.  Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton , 2007, Acta oncologica.

[9]  M. Padrines,et al.  OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. , 2006, Bone.

[10]  P. Anderson.  Osteosarcoma relapse: Expect the worst, but hope for the best , 2006, Pediatric blood & cancer.

[11]  P. Mantyh,et al.  Similarities and Differences in Tumor Growth, Skeletal Remodeling and Pain in an Osteolytic and Osteoblastic Model of Bone Cancer , 2006, The Clinical journal of pain.

[12]  E. Steliarova-Foucher,et al.  Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. , 2006, European journal of cancer.

[13]  A. Potti,et al.  Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation , 2006, Cancer.

[14]  P. Esbrit,et al.  Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand , 2006, Journal of Clinical Pathology.

[15]  Yiwei Li,et al.  Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. , 2006, Cancer research.

[16]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[17]  I. Holen,et al.  Role of osteoprotegerin (OPG) in cancer. , 2006, Clinical science.

[18]  S. Cross,et al.  Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables , 2006, Journal of Clinical Pathology.

[19]  S. Cross,et al.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours , 2006, Journal of Clinical Pathology.

[20]  E. Schwarz,et al.  The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[21]  G. Clines,et al.  Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. , 2005, Endocrine-related cancer.

[22]  S. Cross,et al.  Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival? , 2005, Breast Cancer Research and Treatment.

[23]  N. Nonomura,et al.  Prostate cancer mediates osteoclastogenesis through two different pathways. , 2005, Cancer letters.

[24]  C. Herzog.  Overview of Sarcomas in the Adolescent and Young Adult Population , 2005, Journal of pediatric hematology/oncology.

[25]  E. Kleinerman,et al.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Vessella,et al.  Osteoprotegerin in prostate cancer bone metastasis. , 2005, Cancer research.

[27]  L. Papucci,et al.  In vitro blockade of receptor activator of nuclear factor‐κB ligand prevents osteoclastogenesis induced by neuroblastoma cells , 2004, International journal of cancer.

[28]  M. Padrines,et al.  RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.

[29]  D. Hawkins,et al.  Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy , 2003, Cancer.

[30]  W. Dougall,et al.  Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.

[31]  Paul J. Williams,et al.  Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer , 2003, International journal of cancer.

[32]  M. Wülling,et al.  The origin of the neoplastic stromal cell in giant cell tumor of bone. , 2003, Human pathology.

[33]  H. Shin,et al.  Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. , 2003, Journal of Korean medical science.

[34]  J. Goldman,et al.  Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. , 2003, Blood.

[35]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[36]  G. Mundy,et al.  Mechanisms of osteolytic bone metastases in breast carcinoma , 2003, Cancer.

[37]  Xiaoli Shen,et al.  PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile , 2003, Molecular and Cellular Endocrinology.

[38]  E. Schwarz,et al.  Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[39]  K. Moriyama,et al.  Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma , 2002 .

[40]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[41]  E. Wagner,et al.  Reaching a genetic and molecular understanding of skeletal development. , 2002, Developmental cell.

[42]  F. Hamdy,et al.  Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.

[43]  M. Matsuoka,et al.  Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. , 2002, Blood.

[44]  R. Bataille,et al.  Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. , 2001, Blood.

[45]  J. Michaeli,et al.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[47]  D. Goltzman.  Osteolysis and cancer. , 2001, The Journal of clinical investigation.

[48]  A. Mizokami,et al.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.

[49]  S. Geary,et al.  Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. , 2001, Bone.

[50]  R. Vessella,et al.  Osteoprotegerin and rank ligand expression in prostate cancer. , 2001, Urology.

[51]  K. Ozono,et al.  Receptor Activator of Nuclear Factor κB Ligand (RANKL) Is a Key Molecule of Osteoclast Formation for Bone Metastasis in a Newly Developed Model of Human Neuroblastoma , 2001 .

[52]  Yongwon Choi,et al.  Osteoimmunology: Bone versus immune system , 2000, Nature.

[53]  A. Aboulafia,et al.  Incidence, location, and diagnostic evaluation of metastatic bone disease. , 2000, The Orthopedic clinics of North America.

[54]  F. Craig,et al.  Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. , 2000, Blood.

[55]  T. Guise.  Molecular mechanisms of osteolytic bone metastases , 2000, Cancer.

[56]  A. Zallone,et al.  Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. , 2000, Biochemical and biophysical research communications.

[57]  A. Evdokiou,et al.  Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[58]  M. Zheng,et al.  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. , 2000, The American journal of pathology.

[59]  R. Rizzoli,et al.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.

[60]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[61]  T. Chambers,et al.  Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. , 1999, Endocrinology.

[62]  S. Wysocki,et al.  Gene expression of monocyte chemoattractant protein‐1 in giant cell tumors of bone osteoclastoma: Possible involvement in CD68+ macrophage‐like cell migration , 1998, Journal of cellular biochemistry.

[63]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[64]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  A. Waage,et al.  Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. , 1998, Blood.

[66]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[67]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[68]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[69]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[70]  I. James,et al.  Human osteoclastoma‐derived stromal cells: Correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[71]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[72]  M. Cecchini,et al.  Recent developments in the understanding of the pathophysiology of osteopetrosis. , 1996, European journal of endocrinology.

[73]  S. Wysocki,et al.  Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration. , 1994, The American journal of pathology.

[74]  S. Wysocki,et al.  Detection of mRNA for carbonic anhydrase II in human osteoclast‐like cells by in situ hybridization , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[75]  B. Zee,et al.  Effect of daily etidronate on the osteolysis of multiple myeloma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  N. Clarke,et al.  Morphometric evidence for bone resorption and replacement in prostate cancer. , 1991, British journal of urology.

[77]  M. Jourdan,et al.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. , 1989, The Journal of clinical investigation.

[78]  H. Asaoku,et al.  Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. , 1989, Blood.

[79]  G. Mundy,et al.  Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[80]  S. Goldring,et al.  Human giant cell tumors of bone identification and characterization of cell types. , 1987, The Journal of clinical investigation.

[81]  D. Bertolini,et al.  Bone destruction and hypercalcemia in plasma cell myeloma. , 1986, Seminars in oncology.

[82]  J. McGee,et al.  An immunohistological study of giant‐cell tumour of bone: Evidence for an osteoclast origin of the giant cells , 1985, The Journal of pathology.

[83]  P. Kelly,et al.  Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. , 1975, The New England journal of medicine.

[84]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[85]  W. Dougall,et al.  RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes , 2008, The Prostate.

[86]  P. Kostenuik,et al.  Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis , 2007, Clinical & Experimental Metastasis.

[87]  D. Heymann,et al.  RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. , 2006, International journal of oncology.

[88]  M. Hansen,et al.  Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  Carl W. Miller,et al.  Alterations of thep53, Rb andMDM2 genes in osteosarcoms , 2005, Journal of Cancer Research and Clinical Oncology.

[90]  L. To,et al.  Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. , 2003, Cancer research.

[91]  D. Heymann,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.

[92]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  G. Roodman,et al.  Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. , 2001, Blood.

[94]  J. Papadimitriou,et al.  Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone. , 1999, Pathology.

[95]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[96]  H. Koeffler,et al.  Alterations of the p53, Rb and MDM2 genes in osteosarcoma. , 1996, Journal of cancer research and clinical oncology.

[97]  N. Athanasou,et al.  Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumour of bone. , 1992, Bone and mineral.

[98]  P. Lansdorp,et al.  Production of interleukin-1 by bone marrow myeloma cells. , 1989, Blood.

[99]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[100]  R. Kyle.  Multiple myeloma: review of 869 cases. , 1975, Mayo Clinic proceedings.

[101]  T. Martin,et al.  Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .